financetom
Business
financetom
/
Business
/
Walmart Insider Sold Shares Worth $162,110,475, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Walmart Insider Sold Shares Worth $162,110,475, According to a Recent SEC Filing
May 31, 2024 1:13 AM

03:48 AM EDT, 05/31/2024 (MT Newswires) -- Alice L Walton, 10% Owner, on May 28, 2024, sold 2,495,239 shares in Walmart ( WMT ) for $162,110,475. Following the Form 4 filing with the SEC, Walton has control over a total of 3,664,935,744 shares of the company, with 20,245,740 shares held directly and 3,644,690,004 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/104169/000112760224016995/xslF345X03/form4.xml

Price: 64.87, Change: -0.02, Percent Change: -0.03

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Soccer-Mount returns to boost Man United ahead of Burnley clash
Soccer-Mount returns to boost Man United ahead of Burnley clash
Apr 26, 2024
MANCHESTER, England, April 26 (Reuters) - Manchester United ( MANU ) boss Erik ten Hag will have Mason Mount back for Saturday's Premier League game against Burnley and is hopeful Luke Shaw, Anthony Martial and Lisandro Martinez will return before the season's end. Mount, who has started just seven matches this season across all competitions, had just returned from a...
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump
Apr 26, 2024
10:56 AM EDT, 04/26/2024 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Friday it has signed a deal with Emtora Biosciences for the exclusive, global rights for eRapa, a phase 3-ready drug to treat familial adenomatous polyposis, an inherited condition that affects the gastrointestinal tract. Shares of the company rose more than 81% in recent Friday trading. The license...
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Update: AppFolio Swings to Q1 Adjusted Earnings, Revenue Rises; Lifts 2024 Revenue Guidance; Shares Climb
Apr 26, 2024
11:01 AM EDT, 04/26/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph) AppFolio ( APPF ) shares were up more than 16% in recent trading on Friday, a day after the company posted stronger-than-expected Q1 earnings and raised 2024 revenue guidance. The company reported late Thursday it swung to Q1 adjusted earnings of $1.05...
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe
Apr 26, 2024
11:00 AM EDT, 04/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Friday it will submit a marketing authorization application to the European Medicines Agency for the teprotumumab medicine to treat moderate to severe thyroid eye disease in adults. Teprotumumab is approved for thyroid eye disease treatment in the US, Brazil and Saudi Arabia under the brand name Tepezza, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved